Comparative Pharmacology
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCORTISONE SODIUM SUCCINATE versus STERANE.
HYDROCORTISONE SODIUM SUCCINATE vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone sodium succinate is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory, immunosuppressive, and anti-stress responses. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
100–500 mg IV or IM every 2–6 hours, as needed; typical initial dose 100–250 mg IV bolus followed by 100–250 mg IV every 4–6 hours for acute conditions.
100 mg orally every 12 hours
None Documented
None Documented
1.5-2 hours (plasma terminal); biological half-life 8-12 hours (due to intracellular effects), requiring q6-8h dosing in adrenal insufficiency
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal (90-95% as metabolites, <5% unchanged); biliary/fecal <5%
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category D/X
Category C
Corticosteroid
Corticosteroid